All Photos(1)

Documents

Y0001062

Losartan potassium

Name: Losartan potassium
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing

All Photos(1)

Synonym(s):

2-Butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)(1,1′-biphenyl)-4-yl]methyl}-1H-imidazole-5-methanol monopotassium salt, 2-butyl-4-chloro-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- 1H-Imidazole-5-methanol potassium salt, DuP 753, MK 954, Potassium 5-(4′-((2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-yl)tetrazol-1-ide

Empirical Formula (Hill Notation):

C₂₂H₂₂ClKN₆O

CAS Number:

124750-99-8

Molecular Weight:

461.00

Beilstein:

5845770

MDL number:

MFCD02092704

PubChem Substance ID:

329831243

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

losartan

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]

InChI

1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1

InChI key

OXCMYAYHXIHQOA-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Sigma-Aldrich

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Losartan potassium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Losartan potassium is an orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist. Losartan potassium is used for treatment of hypertension.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1370473

1370495

1370484

1370509

1370510

BP867

Losartan potassium, British Pharmacopoeia (BP) Reference Standard

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

How to Find the Product Number

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503

Product Number

25G

Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

How to Find a Lot/Batch Number for COA

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').
For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').
For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Angiotensin II upregulates K(Ca)3.1 channels and stimulates cell proliferation in rat cardiac fibroblasts.

Li-Ping Wang et al.

Biochemical pharmacology, 85(10), 1486-1494 (2013-03-19)

The proliferation of cardiac fibroblasts is implicated in the pathogenesis of myocardial remodeling and fibrosis. Intermediate-conductance calcium-activated K⁺ channels (K(Ca)3.1 channels) have important roles in cell proliferation. However, it is unknown whether angiotensin II (Ang II), a potent profibrotic molecule

Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome.

Christiane Pees et al.

The American journal of cardiology, 112(9), 1477-1483 (2013-07-23)

Since 2008, when angiotensin II type I receptor blockade with losartan was introduced in the prevention of cardiovascular manifestation of Marfan syndrome (MFS), a specific treatment to address the cardiovascular lesions became available. The present study aimed to compare the

Use of an antifibrotic agent improves the effect of platelet-rich plasma on muscle healing after injury.

Satoshi Terada et al.

The Journal of bone and joint surgery. American volume, 95(11), 980-988 (2013-06-20)

Muscle contusions are a common type of muscle injury and are frequently encountered in athletes and military personnel. Although these injuries are capable of healing in most instances, incomplete functional recovery often occurs because of the development of fibrosis in

ANP and BNP responses to dehydration in the one-humped camel and effects of blocking the renin-angiotensin system.

Abdu Adem et al.

PloS one, 8(3), e57806-e57806 (2013-03-22)

The objectives of this study were to investigate and compare the responses of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in the circulation of hydrated, dehydrated, and dehydrated losartan - treated camels; and to document the cardiac storage

Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects.

M Burnier et al.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 13(1), S23-S28 (1995-07-01)

The evaluation of a new drug in normotensive volunteers provides important pharmacodynamic and pharmacokinetic information as long as the compound has a specific mechanism of action which can be evaluated in healthy subjects as well as in patients. The purpose

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service